Sugi Predict

Sugi Predict / Compounds / SCHEMBL3430447

SCHEMBL3430447

SCHEMBL3430447

NC(=O)c1ccc(NC(=O)c2nn(Cc3ccc(S(=O)(=O)N4CCOCC4)cc3)c3ccccc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 9/20 0.54
▸ MEN1 O00255 8/20 0.54
▸ CYP2D6 P10635 4/20 0.54
▸ CYP2C9 P11712 4/20 0.54
▸ HTT P42858 4/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ CYP2C19 P33261 3/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ S1PR2 O95136 1/20 0.54
▸ TNF P01375 1/20 0.54
▸ NOD1 Q9Y239 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ MAPK1 P28482 3/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ LMNA P02545 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ STAT3 P40763 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428148 0.86 FLT3 (0.55) KMT2ACYP2D6HTTSMN1; SMN2MAPT
SCHEMBL3430294 0.85 ALDH1A1 (0.55) KMT2AMEN1CYP2D6CYP2C9SMN1; SMN2
SCHEMBL3760152 0.77 PTGER4 (0.44) KMT2AMEN1CYP2D6CYP2C9MAPT
SCHEMBL3755332 0.77 KDM4E (0.54) KMT2AMEN1MAPK1GAA
SCHEMBL3428309 0.76 PTGER4 (0.59) KMT2AMEN1SMN1; SMN2MAPTTSHR
SCHEMBL3428968 0.76 FLT3 (0.52) KMT2AHTTSMN1; SMN2RAB9AMAPT
SCHEMBL3428395 0.74 PTGER4 (0.54) KMT2AMEN1
SCHEMBL3430258 0.74 MAPT (0.52) KMT2AMEN1HTTSMN1; SMN2RAB9A
SCHEMBL3428482 0.74 PTGER4 (0.61) SMN1; SMN2TNFNOD1
SCHEMBL3429031 0.74 MEN1 (0.51) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 — — EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 — — US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 — — WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 — — EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 — — US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 — — US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 — — US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KMT2A 2516/4885MEN1 3958/4885CYP2D6 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.